Rising Drug Prices and Health Developments: A Closer Look

Drugmakers will increase prices on 350 drugs, despite pressure from Trump. Vanda Pharmaceuticals' motion sickness drug is FDA-approved. The US court allows Trump's Medicaid cuts to Planned Parenthood in 22 states. Measles cases in South Carolina rise. FDA declines approval for Outlook's and Corcept's drugs.

In a move that could impact millions of Americans, drugmakers plan to raise prices on over 350 medicines in the United States, including several critical vaccines and cancer treatments. This decision comes in the face of ongoing pressure from the Trump administration to curb pharmaceutical costs.

Additionally, Vanda Pharmaceuticals has announced the approval of its new drug for preventing motion-induced vomiting, marking a significant milestone as the first FDA-approved treatment for this condition in over 40 years. The company plans to launch Nereus commercially in the upcoming months.

Elsewhere in the health sector, measles cases in South Carolina have surged, indicating a significant outbreak in the region. Meanwhile, the US FDA has declined approval for drugs from Outlook Therapeutics and Corcept Therapeutics, leading to substantial stock market impacts for both companies.

(With inputs from agencies.)